A Study to Assess Jia Wei Yang He Formula as a Plus Therapy in

Status Recruiting

Clinical Trial Summary

Investigators aimed to assess Jia Wei Yang He Formula as a plus therapy in the treatment of persistent asthma and to explore Airway Microbiome variation of Asthma by Traditional Chinese Medicine treatment

Clinical Trial Description

Asthma is a common chronic inflammatory respiratory disease, patients showed high airway reactivity, and the clinical manifestations of recurrent wheezing, shortness of breath, chest tightness or cough with wheezing dyspnea mainly for a breath. Although many studies have shown that viral infections may be an important cause of asthma seasonal attacks. However, more and more studies have shown that bacterial infection is an important risk factor for asthma. Haemophilus influenzae, Moraxella Mora bacteria infection may increase the risk of asthma by a research report. Chinese medicine decoction, as a common treatment for asthma, can significantly alleviate seasonal attacks and reduce the number of acute attacks. Research shows that Chinese medicine has widely immunomodulatory effects and imbalance of immune system in patients with asthma control, improve the cellular immunity of patients with airway and defense function, significantly reduced asthma attacks of which induced by upper airway infection or chronic persist asthma. This study will be conducted for 4 weeks of standard anti-asthma treatment plus Jia Wei Yang He Formula for patients.Some patients are not willing to use standard treatment such as inhaled corticosteroids and long-acting β-adrenoceptor agonists because of side effects. We will provide these patients free JWYH formula after the efficacy of the JWYH is validated and the subsequent results are considered exploratory. Participants will undergo a physical examination, lung function, blood and sputum collection and all induced sputum samples will be detected by 16S ribosomal RNA (16S rRNA) sequencing and analyzed for microbial bioinformatics. To study whether there is association between the efficacy of Jia Wei Yang He Formula and the changes in microbiota composition. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03299322
Study type	Interventional
Source	Shanghai University of Traditional Chinese Medicine
Contact	Zifeng Ma, Master
Phone	+8621-64385700
Email	mzf05@126.com
Status	Recruiting
Phase	Phase 2
Start date	October 1, 2017
Completion date	December 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02934945` - Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients	Phase 4
Completed	`NCT02561351` - Correlation Between Fractional Exhaled Nitric Oxide (FeNO) Levels and Asthma Exacerbation	N/A
Recruiting	`NCT01759472` - Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Provocation Test	N/A
Completed	`NCT01918293` - Self-Management Using Smartphone Application for Chronic Disease Care in Real siTuation (SMART-Asthma): Adult	N/A
Completed	`NCT01203904` - Pulmicort Turbuhaler 100/200 Specific Clinical Experience Investigation	N/A
Completed	`NCT01762917` - Influence of Bag Volume Variation on the Reproducibility of Inert Gas Rebreathing	N/A
Completed	`NCT00536731` - Symbicort Rapihaler Therapeutic Equivalence Study	Phase 3
Completed	`NCT00331929` - Respiratory Health Study of Children in Kiryat Tivon	N/A
Completed	`NCT00930826` - Childhood Asthma and Schooling: The Truth Unveiled	N/A
Completed	`NCT00327028` - Study of Efficacy of Phenytoin in Therapy of Patients With Bronchial Asthma	Phase 4
Completed	`NCT00413387` - Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)	Phase 3
Completed	`NCT00153283` - Study of Efficacy of Gabapentin in Therapy of Bronchial Asthma	Phase 4
Completed	`NCT00950794` - Study of Salmeterol (SN408D) for Adult Asthma	Phase 4
Completed	`NCT00142025` - Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma	Phase 4
Completed	`NCT00153270` - Study of Efficacy of Sodium Valproate in Therapy of Bronchial Asthma	Phase 4
Completed	`NCT03450434` - XC8 in the Treatment of Patients With Bronchial Asthma	Phase 2
Recruiting	`NCT05189613` - Mepolizumab Effectiveness in Severe Eosinophilic Asthma and Bronchiectasis	N/A
Recruiting	`NCT04128111` - Study on the Correlation Between TCM Syndrome, Inflammatory Phenotype and Biomarker of Bronchial Asthma
Completed	`NCT06326632` - Comparative Effectiveness Study of Constant-Load Versus Graded Aerobic Exercise in Obese Children With Bronchial Asthma	N/A
Completed	`NCT05088512` - The Role of Genetic Factors in the Development of Bronchial Asthma in the Kazakh Population

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Study to Assess Jia Wei Yang He Formula as a Plus Therapy in the Treatment of Persistent Asthma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms